{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:53:39Z","timestamp":1790978019599,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,11,18]],"date-time":"2011-11-18T00:00:00Z","timestamp":1321574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,11,18]],"date-time":"2011-11-18T00:00:00Z","timestamp":1321574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1038\/leu.2011.325","type":"journal-article","created":{"date-parts":[[2011,11,18]],"date-time":"2011-11-18T09:58:51Z","timestamp":1321610331000},"page":"1140-1143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors"],"prefix":"10.1038","volume":"26","author":[{"given":"E","family":"Traer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"MacKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Snead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"Eiring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"O'Hare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B J","family":"Druker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M W","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,11,18]]},"reference":[{"key":"BFleu2011325_CR1","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029\u20131035.","journal-title":"Lancet Oncol"},{"key":"BFleu2011325_CR2","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1182\/blood-2009-01-202606","volume":"114","author":"SW Lane","year":"2009","unstructured":"Lane SW, Scadden DT, Gilliland DG . The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009; 114: 1150\u20131157.","journal-title":"Blood"},{"key":"BFleu2011325_CR3","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood.V85.4.997.bloodjournal854997","volume":"85","author":"BA Roecklein","year":"1995","unstructured":"Roecklein BA, Torok-Storb B . Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6\/E7 genes. Blood 1995; 85: 997\u20131005.","journal-title":"Blood"},{"key":"BFleu2011325_CR4","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","volume":"7","author":"NN Bewry","year":"2008","unstructured":"Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA . Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 2008; 7: 3169\u20133175.","journal-title":"Mol Cancer Ther"},{"key":"BFleu2011325_CR5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1158\/1535-7163.MCT-07-2331","volume":"7","author":"E Weisberg","year":"2008","unstructured":"Weisberg E, Wright RD, McMillin DW, Mitsiades C, Ray A, Barrett R et al. Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther 2008; 7: 1121\u20131129.","journal-title":"Mol Cancer Ther"},{"key":"BFleu2011325_CR6","doi-asserted-by":"publisher","first-page":"6724","DOI":"10.1038\/sj.onc.1210757","volume":"26","author":"SJ Baker","year":"2007","unstructured":"Baker SJ, Rane SG, Reddy EP . Hematopoietic cytokine receptor signaling. Oncogene 2007; 26: 6724\u20136737.","journal-title":"Oncogene"},{"key":"BFleu2011325_CR7","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/sj.leu.2404750","volume":"21","author":"A Pardanani","year":"2007","unstructured":"Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L\/K mutations. Leukemia 2007; 21: 1658\u20131668.","journal-title":"Leukemia"},{"key":"BFleu2011325_CR8","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2009.50","volume":"23","author":"A Pardanani","year":"2009","unstructured":"Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A . CYT387, a selective JAK1\/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009; 23: 1441\u20131445.","journal-title":"Leukemia"},{"key":"BFleu2011325_CR9","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood.V92.10.3780","volume":"92","author":"WS Pear","year":"1998","unstructured":"Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr\/abl-transduced bone marrow. Blood 1998; 92: 3780\u20133792.","journal-title":"Blood"},{"key":"BFleu2011325_CR10","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood.V92.10.3829.422k14_3829_3840","volume":"92","author":"X Zhang","year":"1998","unstructured":"Zhang X, Ren R . Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998; 92: 3829\u20133840.","journal-title":"Blood"},{"key":"BFleu2011325_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129\u2013141.","journal-title":"Cancer Cell"},{"key":"BFleu2011325_CR12","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/leu.2009.299","volume":"24","author":"DK Hiwase","year":"2010","unstructured":"Hiwase DK, White DL, Powell JA, Saunders VA, Zrim SA, Frede AK et al. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia 2010; 24: 771\u2013778.","journal-title":"Leukemia"},{"key":"BFleu2011325_CR13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1177\/1947601910372232","volume":"1","author":"AK Samanta","year":"2010","unstructured":"Samanta AK, Chakraborty SN, Wang Y, Schlette E, Reddy EP, Arlinghaus RB . Destabilization of Bcr-Abl\/Jak2 Network by a Jak2\/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML). Genes Cancer 2010; 1: 346\u2013359.","journal-title":"Genes Cancer"},{"key":"BFleu2011325_CR14","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1182\/blood.V97.7.2008","volume":"97","author":"X Sun","year":"2001","unstructured":"Sun X, Layton JE, Elefanty A, Lieschke GJ . Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571. Blood 2001; 97: 2008\u20132015.","journal-title":"Blood"},{"key":"BFleu2011325_CR15","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","volume":"109","author":"Y Wang","year":"2007","unstructured":"Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation. Blood 2007; 109: 2147\u20132155.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2011325.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011325","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011325.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:41:05Z","timestamp":1648737665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2011325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,18]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["BFleu2011325"],"URL":"https:\/\/doi.org\/10.1038\/leu.2011.325","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,18]]},"assertion":[{"value":"18 November 2011","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}